Media & Press relations

Our latest press releases

October 22, 2026

bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE^® SPOTFIRE^® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics

bioMérieux's BIOFIRE® SPOTFIRE® Vaginitis (VG) Panel has received Dual 510(k) Clearance and CLIA Waiver* from the U.S. Food and Drug Administration (FDA).

Discover more

Swipe for more

October 19, 2026

WHO Grants Emergency Use Listing for BIOFIRE® Global Fever Special Pathogens Panel, Expanding Access to Differential Diagnostics for the Ebola Response

bioMérieux, a world leader in in vitro diagnostics, announced that the World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the BIOFIRE® Global Fever Special Pathogens Panel, strengthening access to differential diagnostic testing in support of the ongoing Ebola Bundibugyo outbreak affecting the Democratic Republic of the Congo (DRC) and neighboring countries.

Read more
September 14, 2026

First-Half 2026 Results

bioMérieux's Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26.

Read more
September 13, 2026

bioMérieux Highlights Positive Impacts of Rapid, Accurate Diagnostics for Patients and Accepts Industry Awards at ADLM 2026

bioMérieux hosted a press panel and accepted seven 2026 IMV ServiceTrak™ Clinical Laboratory Awards. These awards highlight bioMérieux’s continued commitment to delivering industry-leading diagnostic solutions and exceptional customer support to clinical laboratories.

Read more